Interim versus standard methadone treatment: A benefit-cost analysis

Robert P. Schwartz, Pierre K. Alexandre, Sharon M. Kelly, Kevin E. O'Grady, Jan Gryczynski, Jerome H. Jaffe

Research output: Contribution to journalArticlepeer-review

Abstract

A benefit-cost analysis was conducted as part of a clinical trial in which newly-admitted methadone patients were randomly assigned to interim methadone (IM; methadone without counseling) for the first 4. months of 12. months of methadone treatment or 12. months of methadone with one of two counseling conditions. Health, residential drug treatment, criminal justice costs, and income data in 2010 dollars were obtained at treatment entry, and 4- and 12-month follow-up from 200 participants and program costs were obtained. The net benefits of treatment were greater for the IM condition but controlling for the baseline variables noted above, the difference between conditions in net monetary benefits was not significant. For the combined sample, there was a pre- to post-treatment net benefit of $1470 (95% CI: -$625; $3584) and a benefit-cost ratio of 1.5 (95% CI: 0.8, 2.3), but using our conservative approach to calculating benefits, these values were not significant.

Original languageEnglish (US)
Pages (from-to)306-314
Number of pages9
JournalJournal of Substance Abuse Treatment
Volume46
Issue number3
DOIs
StatePublished - Mar 2014

Keywords

  • Benefit-cost
  • Interim methadone
  • Methadone treatment

ASJC Scopus subject areas

  • Phychiatric Mental Health
  • Medicine (miscellaneous)
  • Clinical Psychology
  • Psychiatry and Mental health

Fingerprint Dive into the research topics of 'Interim versus standard methadone treatment: A benefit-cost analysis'. Together they form a unique fingerprint.

Cite this